CJC-1295 w/ DAC
CJC-1295 w/DAC Primer
What is CJC-1295 w/ DAC?
CJC-1295 w/ DAC is a synthetic peptide hormone designed to stimulate the release of growth hormone (GH) from the pituitary gland. It is a modified version of Growth Hormone Releasing Hormone (GHRH), a naturally occurring hormone that regulates GH production. The "DAC" portion of the name refers to Drug Affinity Complex, a technology used to increase the peptide's half-life and stability in the body.
How Does it Work?
Mimics GHRH: CJC-1295 binds to receptors on the pituitary gland, mimicking the action of GHRH and triggering the release of stored GH.
Extended Half-Life: The DAC modification allows CJC-1295 to bind to albumin (a protein in the blood), which protects it from degradation and extends its duration of action.
Potential Benefits:
Increased GH Levels: By stimulating the release of GH, CJC-1295 may promote muscle growth, fat loss, improved sleep, enhanced skin elasticity, and strengthened immune function.
Longer-Lasting Effects: The DAC modification means that less frequent injections may be needed compared to other GHRH analogs.
Research and Clinical Applications:
Research: CJC-1295 has been studied in animal models and some human trials, primarily focusing on its effects on GH secretion and potential therapeutic applications.
Clinical Applications: While not currently approved for medical use, CJC-1295 is being investigated for its potential in treating conditions such as GH deficiency, muscle wasting, and aging-related decline.
Important Considerations:
Side Effects: Potential side effects may include water retention, joint pain, carpal tunnel syndrome, and increased appetite.
Regulation: CJC-1295 is not approved by regulatory bodies like the FDA and is primarily available for research purposes.
Long-Term Effects: The long-term effects of CJC-1295 are not fully understood. More research is needed to assess its safety and efficacy for prolonged use.
Administration: CJC-1295 is typically administered via subcutaneous injection.